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ABSTRACT
Knowledge of the fundamental epigenetic mechanisms
governing gene expression and cellular phenotype are
sufficiently advanced that novel insights into the
epigenetic control of chronic liver disease are now
emerging. Hepatologists are in the process of shedding
light on the roles played by DNA methylation, histone/
chromatin modifications and non-coding RNAs in specific
liver pathologies. Alongside these discoveries are
advances in the technologies for the detection and
quantification of epigenetic biomarkers, either directly
from patient tissue or from body fluids. The premise for
this review is to survey the recent advances in the field
of liver epigenetics and to explore their potential for
translation by industry and clinical hepatologists for the
design of novel therapeutics and diagnostic/prognostic
biomarkers. In particular, we present findings in the
context of hepatocellular carcinoma, fibrosis and non-
alcoholic fatty liver disease, where there is urgent unmet
need for new clinical interventions and biomarkers.
INTRODUCTION
Irrespective of aetiology, the progression of chronic
liver damage and inflammation to cirrhosis and/or
cancer is highly variable between individuals. If
liver damage persists, a large percentage of patients
can expect their disease to advance over their life-
time. However, the course and rate of progression
of their disease is often unpredictable using prog-
nostic tools currently available in the clinic. As an
example, a recent study of paired biopsies from
108 patients with non-alcoholic fatty liver disease
(NAFLD) revealed that 42% patients had fibrosis
progression, 40% had no change in fibrosis, while
18% had fibrosis regression; 9% underwent pro-
gression from bland steatosis to fibrosing-
steatohepatitis.1 However, the degree of progres-
sion was variable, ranging from one to three stages,
and the molecular basis for this variability remains
poorly defined. While genome-wide association
studies (GWAS) have identified genetic variants that
show association with fibrosis and/or hepatocellular
carcinoma (HCC),2 3 to date their predictive value
with regard to outcomes in clinical practice have
been limited. Furthermore, the biological function
of variants remains challenging to elucidate and
direct patient benefit appears distant. It is well
established that there are numerous non-genetic
factors that influence the progression of liver
disease, including patient age, sex, body compos-
ition, diet, exercise, microbiome, alcohol consump-
tion and their history of smoking.4 The study of
epigenetics is, in essence, the investigation of how
non-genetic factors act upon the genome to influ-
ence gene expression and phenotype. Epigenetics
can therefore enable us to interrogate the mechan-
isms that underlie disease phenotype, and it is
hoped to shed new light on the basis for interpati-
ent variability in disease progression. Furthermore,
the highly dynamic nature of epigenetic mechan-
isms and their regulators in response to environ-
mental cues offers hope for the advent of
epigenetic therapies in liver disease, as is now
occurring in clinical oncology. However, this dyna-
mism, coupled with the complexity of epigenetic
mechanisms that can operate both locally at the
gene level as well as globally across the epigenome,
presents significant challenges. Improvements in
next generation sequencing technologies and their
ability to generate genome-wide quantitative data
are helping to meet this challenge. As an example,
DNA methylation can now be quantified in a
sequence-specific manner across the entire genome
to generate a methylome map, and there is poten-
tial to carry this out on either single cells or circu-
lating free DNA.5 6 Similarly, emerging omics
approaches to the study of histone modifications
will offer unparralled insights into the functional
associations of alterations in the chromatin land-
scape of cells and disease processes. In this review,
we will describe the basic epigenetic players and
mechanisms before discussing recent important dis-
coveries in liver epigenetics.
EPIGENETICS AND THE CASE FOR ITS STUDY
IN LIVER DISEASE
Conrad Waddington established the field of epigen-
etics in 1942 when he proposed an uncoupling of
genotype and phenotype, implying that regulatory
processes linked the two.7 The first conclusive evi-
dence that cellular phenotype is dictated by
mechanisms other than that encoded within the
DNA sequence came from classic experiments in
frogs, for which Sir John Gurdon was later
awarded the Nobel prize. He demonstrated that
transplantation of a nucleus from a fully differen-
tiated somatic cell into a denucleated egg supported
the development of a tadpole. The conclusion was
that the genome sequence is stable through devel-
opment and is not per se determining phenotype;
rather the latter is dictated by developmentally pro-
grammed patterns of gene expression that are
responsive to the cellular microenvironment.8 The
mechanisms that regulate this flow of genetic infor-
mation include the actions of key transcription
factors (as demonstrated by the experiments of
Shinya Yamanaka, who shared the 2012 Nobel
prize with Gurdon) that operate in concert with
epigenetic factors to modulate the rate at which
individual genes are transcribed into RNA.
Critically, the activities of epigenetic and
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transcription factors are plastic and highly dynamic, being influ-
enced by the metabolic state of the cell and its ever changing
extracellular environment. In turn, even the most differentiated
population of nucleated cells will display phenotypic heterogen-
eity and have the potential for behavioural reprogramming. The
normal healthy functions of the liver, as with any tissue, are crit-
ically dependent upon robust maintenance of the behavioural
properties of its constituent cells. Unhealthy perturbation of
liver function reflects a loss of homeostasis, whereby the con-
stituent liver cells fail to maintain their distinct phenotypic
characteristics in the face of challenges in the local microenvir-
onment induced by metabolic, xenobiotic, immune or microbial
triggers. Hence, by illuminating the epigenetic modifications
that are associated with specific pathologies such as cirrhosis or
cancer we can better understand the molecular basis for loss of
cellular homeostasis in chronic liver disease (box 1).
THE MAJOR EPIGENETIC MECHANISMS
DNA methylation
DNA can be covalently modified and the best-known modifica-
tion is methylation of cytosine at its 5th carbon ring, which is
mainly, although not exclusively, found at cytosines within CpG
dinucleotides. The most well-established role of the me-CpG
mark is when it occurs at high density within the so-called CpG
islands which predominantly traverse 50 promoter regions;
methylation at these regions results in strong transcriptional
repression. Importantly, methyl-CpG is a signal for recognition
of DNA by specific proteins containing a so-called methyl
binding domain (MBD). The MBD family (MBD1, MBD2,
MeCP2 and MBD4) mediate transcriptional repression at CpG
islands.9 The majority of methylated CpG islands are develop-
mentally established and become stable in the adult. However in
cancer, methylation can be acquired at normally unmethylated
CpG islands and is usually accompanied by a second repressive
epigenetic mark, methylation of histone H3 at its lysine 27
residue, which compacts chromatin and inhibits transcription.10
Genome-wide, single-base resolution mapping of DNA methyla-
tion has revealed that there is considerable dynamic turnover
outside of CpG islands and suggests that the occupancy of tran-
scription factors at these CpG sites is associated with loss of
methylation.11 12 Despite this knowledge, there is at present
inconclusive evidence that loss of methylation outside CpG
islands instructs transcriptional information at a local level.
Further insights may emerge now that the enzymes that instruct
DNA methylation (DNA methyltransferases: DNMT1,
DNMT3a and DNMT3b) and demethylation (ten-eleven trans-
location enzymes [TET1–3]) are beginning to be functionally
defined. DNMT1 is a maintenance methylase that during cell
division recognises a hemimethylated site on a new DNA strand
and regenerates the bimethylated state.13 In this way, CpG
Box 1 An epigenetic glossary
5-hydroxymethylcytosine: the oxidation of 5-methylcytosine modified DNA, by the Tet family of enzymes.
5-methylcytosine: an epigenetic modification of DNA occurring at CpG dinucleotides.
Bisulfite conversion: the selective deamination of unmethylated cytosine bases to uracil by treatment with sodium bisulfite; used for
methylation analysis.
Chromatin: the formed complex of DNA and histones required for nuclear compaction.
CpG islands: regions of DNA enriched for CpG dinucleotides; CpG islands are >200 bp long, located at transcriptional start sites, and
predominantly unmethylated.
Differentially methylated region: regions of DNA in an organisms genome that is methylated differentially between disease phenotypes.
DNA methylation: an epigenetic modification in which a methyl group is covalently bonded to the 5th carbon of the cytosine pyrimidine
ring in a CpG dinucleotide, frequently (but not exclusively) associated with gene silencing.
DNA methyltransferases: a group of enzymes that catalyse the addition of a methyl group to DNA. Members include DNMT1 required for
maintenance of DNA methylation and DNMT 3a/b involved in de novo methylation.
Euchromatin: unpacked chromatin, allowing access for transcription factors and gene expression.
Heterochromatin: compacted chromatin, inaccessible to transcription factors, containing poorly expressed genes.
Histone acetyltransferase: enzyme that acetylates histones at specific lysine residues.
Histone deacetylase: enzyme that remove acetyl groups from N(6)-acetyl-lysine residues on a histone.
Histone: the core protein around which DNA is wound tight, ordering DNA into nucleosomes. Core histones include H2A, H2B, H3 and H4.
Histone modification: post-translational modifications of histones including the addition or removal of methylation, acetylation,
phosphorylation, ubiquitination, sumoylation and marks.
Histone variants: variant proteins that can be inserted into nucleosomes, and may have intrinsic gene regulatory functions.
Long non-coding RNA: non-protein-coding RNA>200 nucleotides with gene regulatory properties. Examples include Xist, HOX transcript
antisense intergenic RNA, highly upregulated in liver cancer and high expression in hepatocellular carcinoma.
microRNA: Small non-protein coding RNA (∼22 nucleotides) that regulate cellular processes by controlling transcription and translation
of mRNA.
Non-coding RNA (ncRNA): the majority of the genome is transcribed into non-protein encoding RNA, involved in many cellular processes.
Examples include microRNAs, small interfering RNAs (siRNAs), Piwi-interacting RNAs, long non-coding RNAs (lncRNAs) and long
intergenic RNAs.
Nucleosome: the basic structural unit of chromatin, allowing compaction; one nucleosome is comprised of 147 bp of DNA wrapped
around a histone octamer including two molecules each of the core histones H2A/B, H3 and H4.
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methylation patterns are faithfully maintained in daughter cells.
However, de novo methylation does occur in the absence of cell
division and is regulated by DNMT3a and DNMT3b.14 The
TET enzymes catalyse the step-wise oxidation of methyl groups
on DNA leading to the eventual restoration of the unmodified
cytosine residue.15 Experimental deletion of the TET enzymes
results in increased methylation at gene enhancers and subtle
alterations in the expression of genes linked with these enhancer
regions.16 17 Turnover of DNA methylation may therefore be an
ongoing process in most cell types and has potential to be
modulated via changes in the relative expression of DNMT and
TET proteins. The discovery that vitamin C can enhance TET
activity in cells supports this idea and indicates the existence of
mechanisms for modulating DNA methylation in response to
environmental cues.18
Histone modifications and chromatin remodelling
In order to achieve the feat of compaction required for 2 m of
DNA to be condensed into a human nucleus, DNA interacts
with specialised proteins to form tightly packed chromatin; for
chromosomal processes to occur such as gene transcription, this
must be iteratively unpacked and repacked in a regulated
manner, providing an opportunity for dynamic gene regulation.
The most basic level of chromatin packing is known as the
nucleosome, each core particle consisting of 147 bp of double
stranded DNA wrapped around a complex of eight histone pro-
teins (two copies each of H2A, H2B, H3 and H4) seen under
an electron microscope as ‘beads on a string’; linker DNA being
the string and the beads representing the nucleosome core par-
ticle. Each of the core histones has an unstructured N-terminal
amino acid tail extension that can be subject to a plethora of
covalent, post-translational modifications that control aspects of
chromatin structure and function, either directly affecting chro-
matin structure or comprising signals to be recognised by
protein effectors.19 Histones can be acetylated, methylated on
lysine and arginine, phosphorylated on serine, ubiquitinated,
sumoylated and ADP-ribosylated. Histone acetylation loosens
chromatin to transcriptionally active euchromatin. By contrast,
trimethylation of lysine 9 of histone 3 (H3K9me3) and
H3K27me3 are associated with condensed, transcriptionally
silent heterochromatin. However, histone lysine methylation can
also promote transcription depending on which lysine is modi-
fied for example, H3K4me3 and H3K36me2/3 are generally
associated with euchromatin. Variants of the core histones
(except H4) can be inserted by ATP-dependent chromatin-
remodelling complexes and regulate nucleosome structure. As
an example, exchange of H2 for H2A.Z is important for gene
expression,20 while exchange for macroH2A is associated with
transcriptional repression.21 Histone modifications are highly
dynamic, and regulated by ‘writer’ and ‘eraser’ enzymes that
add or remove post-translational modifications, respectively.
They can serve as marks for recruitment of ATP-dependent
chromatin remodelling complexes such as switch/sucrose non-
fermentable (SWI/SNF) that remodel nucleosome and chromatin
structure allowing access to gene regulatory proteins; mamma-
lian SWI/SNF can slide nucleosomes on DNA or can exchange
or extrude histones, promoting gene activation.10 In contrast,
repressive chromatin remodellers act on nucleosomes to form
densely packed chromatin, restricting access to transcription
factors and recruiting other chromatin modifiers that help
impose repression. Polycomb group proteins are found in two
multiprotein complexes known as polycomb repressor com-
plexes 1 and 2 (PRC1 and PRC2) and play a major role in cell
differentiation. PRC2 regulates chromatin structure, in part by
H3K27 trimethylation through its enzymatic subunit EZH2.
The PRC1 complex monoubiquitylates H2AK119 via the ubi-
quitin ligases RING1A and RING1B; PRC1 can also bind to
H3K27me3 formed by PRC2 catalysis and both act to repress
gene expression.22
Non-coding RNAs
A large amount of the transcribed genome is structured such
that it is not destined to be translated into proteins but instead
carries out regulatory functions in RNA forms known as non-
coding RNAs (ncRNAs).23 MicroRNAs (miRNAs), which are
sequence-specific 22-nucleotide RNA molecules, are by far the
most intensively studied and functionally best characterised
ncRNAs. The mechanism by which miRNA regulate gene
expression is to modulate the translation of their target mRNAs
and this usually results in downregulation of protein expression.
A number of key regulatory miRNA have already been devel-
oped as targets for antiviral24 and anticancer drug targets25 and
are implicated in the control of liver fibrosis.26 Many other
classes of ncRNA have been discovered including ribosomal
RNAs, ribozymes, endogenous small interfering RNAs,
Piwi-associated RNAs and long non-coding RNAs (lncRNAs).
Readers are referred to an excellent recent review on these
molecules.27 LncRNAs are >200 nucleotides in length that can
be further classified into antisense lncRNAs that overlap known
protein-coding regions, intronic lncRNAs, overlapping tran-
scripts and long intergenic RNAs encoded in the intergenic
space between protein-coding regions. LncRNAs are implicated
as regulators of a wide variety of biological processes relevant to
liver homeostasis and disease including cell proliferation, differ-
entiation, migration and survival, yet surprisingly for the major-
ity of lncRNAs their precise mechanisms of action are obscure.
The best-studied lncRNA function is in X chromosome inactiva-
tion in which the 17 kb transcript Xist recruits repressive epigen-
etic factors such as PRC2 to bring about effective repression of
gene transcription and ensure appropriate X chromosome gene
dosaging in females.28 The lncRNA Tsix can recruit Dnmt3a,
while Kcnq1ot1 recruits Dnmt1; these observations indicating
that lncRNAs may act as guides for bringing CpG methylases to
specific sites in the genome.29 30 lncRNAs may therefore reveal
how DNA methylation and histone modifications are annotated
in a gene-specific and sequence-specific manner during and after
development. However, the actions of lncRNAs extend to many
other biological processes including the regulation of transcrip-
tion factor binding, mRNA processing, mRNA stability, protein
translation and signal transduction.23
EPIGENETIC MECHANISMS IN HCC
DNA methylation and HCC
Typical epigenetic lesions in human cancer include a
genome-scale loss of DNA methylation, with loci-specific de
novo hypermethylation at gene promoters of tumour suppressor
genes (TSGs) leading to transcriptional repression of down-
stream TSGs; such aberrations may have potential as diagnostic
markers in the progression of HCC. There are many studies
reporting HCC-specific DNA methylation changes, notably
some at a genome-wide level.31–35 Of these, the largest study to
date profiled the DNA methylation landscape in 221 patients
with HCC treated with surgical resection of a predominantly
viral aetiology (66%). In this study, 485 000 CpG dinucleotides
were interrogated using methylation array technology; a
36-probe hypermethylation signature, termed a DNA methyla-
tion mortality index (MI), accurately predicted survival in
patients with HCC, independent of known clinical and
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pathological risk factors for survival (HR: 13.35; 95% CI 7.94
to 22.42; p<0.001).36 DNA methylation MI was also an inde-
pendent predictor of overall recurrence (HR: 5.8; 95% CI 3.1
to 11; p<0.001). This was validated in an independent cohort
of predominantly alcohol-related, aggressive tumours.
Combined with transcriptomics, the study identified mRNA sig-
natures enriched with progenitor cell features such as epithelial
cell adhesion molecule (EpCAM) and S2 (p=0.009 and
p=0.006, respectively) in the DNA methylation MI high
group.36 The landscape of aberrant methylation in human HCC
displayed general hypomethylation compared with normal liver,
mainly located in the intergenic (39.9%) and body regions
(34.5%), whereas hypermethylated probes were generally in
promoter areas (50.5%). In relation to CpG islands, hyper-
methylation occurred at the islands and shores (63.9% and
24.8%), whereas hypomethylation were mainly in open sea
regions (63.55%).36 Gene ontology analysis showed the
top-ranked probes included genes related to expression regula-
tion, and deregulated signalling cascades such as insulin growth
factor (IGF), phosphatidylinositol 3-kinase, transforming
growth factor β (TGF-B), WNT signalling and cadherin.36
Finally, the study demonstrated aberrant methylation in known
and candidate epidrivers of disease. Hypermethylation was con-
firmed, as demonstrated in prior studies, in well-known TSGs
such as RASSF1, APC, NEFH34 and NOTCH3;37 candidate epi-
drivers included SEPT9 a tumour suppressor in colon and
ovarian cancer.38 This recent study, when added to previous
genome-wide DNA methylation studies, confirms the crucial
role of deregulated DNA methylation in human HCC develop-
ment and critically survival outcome.
Despite much enthusiasm for genome scale epigenetic studies
in HCC, there remains a clear caveat when interpreting the clin-
ical and biological meaning of such data. Critically, cancerous
tissue represents a heterogeneous mix of tumour cells, fibro-
blasts, stromal cells, inflammatory cells and non-parenchymal
cells. Thus, any methylation signatures may simply be due to
changes in numbers of cells and constituents, rather than direct
methylation changes in cancer cells, relevant to cancer biology.
Further genome-wide studies should utse technologies such as
laser capture microdissection or high-speed cell sorting to separ-
ate tumour cells from contaminating cells.
The functional relevance of aberrant DNA methylation needs
to be rigorously assessed. Only a handful of studies have tested
potential aberrantly methylated TSGs in vivo;34 39 40 in a recent
study, 71 HCC samples were subjected to low density methyla-
tion array, after exposure to 5-aza-20-deoxycytidine to reverse
DNA methylation. Of 13 candidate TSGs, 2 (SMPD3 and
NEFH) were further functionally tested; knocking down these
genes with small hairpin RNA promoted cell invasion and
migration in vitro, and increased tumour formation after sub-
cutaneous injection or transplantation into mice.34 Reduced
levels of SMPD3 were associated with early recurrence after
curative resection.34 Although these data provide good evidence
for a functional role of DNA methylation and gene expression
in candidate TSGs, ideally, direct functional correlation between
aberrant methylation and altered gene expression requires in
vivo loci-specific manipulation of DNA methylation and demon-
stration of a correlation with a change in gene expression; such
studies are greatly anticipated.
Preliminary studies are beginning to show the feasibility of
measuring circulating cell-free tumour DNA (cfDNA) methyla-
tion for early diagnosis of HCC. In one such study, plasma
DNA had detectable hypermethylation (>5%) for CDKL2,
CDKN2A, HIST13G, STEAP4 and ZNF154 in 37%–63% of
patients with HCC (n=38).33 Clearly, further studies with
larger patient cohorts are needed to fully assess the utility of
this approach, although similar results have been found in other
solid organ cancers.41 Finally, tumour methylation patterns can
be detected in cfDNA and short cfDNA fragments can harbour
footprints of transcription factor binding. This information cor-
relates with tissue nucleosome occupancy and transcription
factor binding, informing the cell type of origin of cancers such
as the liver,42 providing another non-invasive epigenetic
approach to disease monitoring.
Chromatin remodellers and HCC
Perhaps the best-studied deregluated master chromatin remodel-
ler in HCC is EZH2, the catalytic subunit of the PRC2
complex. EZH2 is overexpressed in HCC and is associated with
malignant progression, vascular invasion and cell proliferation.43
A progressive increase in EZH2 protein expression from dys-
plastic nodule to early HCC is associated with advanced
HCC.44 EZH2 protein expression can serve as a biomarker dis-
tinguishing preneoplastic lesions from HCC (area under the
receiver operating characteristic (AUROC)=0.935) and positive
expression of EZH2 correlates with reduced survival.45 In vivo
studies in nude mice show a key role for EZH2 in HCC
tumourigenesis; intratumoral EZH2 knockdown produced sig-
nificant tumour regression and suggest EZH2 as a promising
target for therapeutics.46 EZH2 was found to repress several
negative regulators of the Wnt pathway, activating
β-catenin-mediated cellular proliferation.47 A recent study found
that EZH2 and its structural partners EED, SUZ12 and RBP7
contribute to tumourigenesis by silencing multiple tumour sup-
pressor miRNAs48 including miR-101, a recently characterised
negative regulator of both EZH2 and EED.49 EZH2 also regu-
lates expression of the chemokine receptor CXCR4 by control-
ling expression of its regulator miR-622 and patients with
overactivity of this pathway have a worse overall survival.50
Mutational exome screening of viral-related and alcohol-
related tumours revealed recurrent inactivating alterations in
ARID1A and ARID2 in 15% and 5% of tumours, respect-
ively;51 52 both proteins are part of the SWI/SNF ATPase-related
chromatin-remodelling complex, shown to have tumour sup-
pressor functions.53 Exome sequencing in 87 HCCs and
matched non-tumour tissue of viral origin revealed missense
gene mutations encoding H3K4 methyltransferases MLL1,
MLL2, MLL3 and MLL4. The functional effect of these muta-
tions on histone methylation are yet to be validated, but these
enzymes are important transcriptional coactivators required for
expression of p53 target genes subsequent to DNA damage.54
ncRNAs in HCC
Of the ncRNAs it is unsurprising that miRNAs are the most
extensively studied in HCC, for this class of ncRNAs readers
are referred to a recent detailed review.55 By contrast, only a
handful of lncRNAs have been validated and functionally char-
acterised as important in regulating the biology of HCC. Highly
upregulated in liver cancer (HULC), a 500 nt transcript discov-
ered by cDNA microarray is upregulated 33-fold in HCC.56
siRNA knockdown of HULC deregulates a number of
proliferation-related and HCC-related genes. Of note, HULC
RNA is detected in peripheral blood cells of patients with HCC,
raising the possibility of novel biomarker.56 Further functional
clarification in hepatoma cells showed that HULC acts by pro-
moting lipogenesis through ACSL1 activation, disturbing the
Clock circadian regulator/brain and muscle arnt-like protein-1
complex57 58 and promoting angiogenesis.59 HOX transcript
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antisense intergenic RNA (HOTAIR) is a 2158 nt PRC2-interacting
lncRNA upregulated in HCC that is predictive of tumour recur-
rence in liver transplant patients.60 Knockdown of HOTAIR in
hepatoma cell lines sensitised to TNFα-induced apoptosis and
reduced cell viability.60 A recent study validated the upregula-
tion of HOTAIR in HCC specimens and siRNA knockdown of
HOTAIR inhibited cell growth, induced cell cycle arrest and
suppressed tumourigenesis.61 Mechanistically, HOTAIR nega-
tively regulates miR-218 by recruiting EZH2 to its promoter;
this results in overexpression of Bmi-1, a target of miR-218 and
subsequent inactivation of p14ARF and p16Ink4a, two TSGs61
(see figure 1).
High expression in hepatocellular carcinoma (HEIH) was dis-
covered after genome-wide screening HBV-related HCCs by
microarray and is known to interact with EZH2.62 High expres-
sion of this lncRNA was associated with worse patient survival,
and knockdown of HEIH resulted in upregulation of PRC2
target genes such as p16Inka.62 Next generation sequencing
studies are expanding the list of lncRNAs involved in HCC; in a
recent study a number of novel lncRNAs were found to be dif-
ferentially expressed in HCC.63 However, known deregulated
lncRNAs in HCC, HULC and H19, were not validated in this
study.63 Future studies using next generation sequencing will
certainly illuminate the role of lncRNAs in hepatocarcinogenesis
and are greatly anticipated.
Direct oncogenic roles of viruses by epigenetic deregulation
Viral-aetiology tumours can provide understanding of the rela-
tionship between epigenetic dysregulation and cancer biology.
Viral proteins, such as HBx, can affect chromatin and transcrip-
tional control promoting regional hypermethylation and global
hypomethylation. HBx can conduct targeted deregulation of
DNMT1, DNMT3A1 and DNMT3A2, increasing their activity
and repressing IGF3 and p16INK, through de novo hypermethy-
lation; global hypomethylation of satellite 2 repeat sequences
was induced by decreasing DNMT3B.64 Another study showed
HBx-directed recruitment of DNMT3A to IL4R and MT1F pro-
moters and subsequent de novo hypermethylation.65 A further
proposed mechanism for HBx is to enhance DNMT1 expres-
sion through downregulation of its repressor miR-152.66
Silencing of miR-152 results in global DNA hypermethylation
and increases methylation levels at two tumour suppressor
genes, GSTP1 and CDH1.66 HBx can also stimulate active
demethylation and derepression of the EpCAM gene, known to
be observed in HBV-aetiology HCC. The NF-κB transcription
factor RelA directs this effect by the formation of a DNA
demethylation complex comprising TET2, the catalytically
inactive DNMT3L and EZH2.67 HCV can also directly alter
DNA methylation. Gadd45β controls cell cycle, growth arrest
and DNA repair and is under expressed in HCV-tumour tissue.
The Gadd45β promoter is hypermethylated in HCV transgenic
mouse liver and in cells infected with the JFH1 strain of HCV.68
Chimeric mice with humanised livers showed time-dependent,
genome-wide changes in DNA methylation after intravenous
injection with HBV or HCV.69 Importantly, a number of
common genes were methylated in this mouse model when
compared with human HCC samples indicating that the model
may be an important tool for interrogating clinically relevant
virus-induced epigenome remodelling.69
Viruses can also directly alter epigenetic reprogramming
linked to oncogenic transformation. In both cellular and animal
models, and HBV-related HCC, HBx induces the
PLK1-dependent proteosomal degradation of repressive chroma-
tin regulating proteins, SUZ12 (a component of PRC2) and
ZNF198 by ubiquitination, leading to overexpression of hepatic
stem cell cancer-related genes such as EpCAM; lncRNA
HOTAIR seems to act as a ubiquitination scaffold.70 HBV inte-
gration into the host genome can generate a viral-human hybrid
RNA transcript that acts as a lncRNA; HBx-LINE1, a fusion
human LINE1 and HBx gene has been identified in HBV-positive
HCC and can drive migration and invasion of tumour cell lines
by epithelial to mesenchymal transition and nuclear localisation
of β-catenin.71 A recent study demonstrated that HBxLINE1 pro-
motes carcinoma progression by sequestering miR-122 as a
molecular sponge.72
EPIGENETICS AND LIVER FIBROSIS
Liver fibrosis is defined by the excessive accumulation of extra-
cellular matrix and scar formation, in the context of chronic
damage to the liver. Eventually regenerating hepatocyte nodules
form, defining the progression to cirrhosis; hepatocellular
cancer and liver failure can ultimately develop with transplant-
ation the only treatment.73 However, the progression to end-
stage disease is not linear, but nuanced in that only a small minor-
ity of patients progress to severe disease. At the heart of this lies
an interplay between host genetics or mutations and environmen-
tal factors, determining the phenotype of the patient in response
to chronic liver injury. Recent studies have provided evidence that
DNA methylation is a critical event governing the molecular
events underpinning fibrogenesis and disease progression.
Hepatic stellate cell (HSC) transdifferentiation, from a
vitamin A storing pericyte, to a profibrogenic myofibroblastic
phenotype, is a pivotal event in fibrogenesis; it occurs in
response to a variety of external stimuli such as inflammation
and hepatocellular damage. Transdifferentiation requires trigger-
ing and orchestrating epigenome-wide reprogramming to sup-
press adipogenic differentiation factors, de novo expression of
myofibroblast regulating transcription factors, and cell cycle
Figure 1 HOTAIR-mediated
carcinogenesis. Hotair acts a guide, (A)
redirecting the PRC (EZH2, SUZ12,
EED) and H3K27me3 patterns
favouring tumour metastasis and (B)
silencing of miR-218 that promotes cell
proliferation through aberrant
activation of Bmi-1. HOTAIR, HOX
transcript antisense intergenic RNA;
PRC, polycomb repressor complex.
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entry. HSC activation can be inhibited both in vitro and in vivo
by small molecule epigenetic inhibitors such as the DNMT1
inhibitor 5-azadeoxycytidine and the EZH2 inhibitor
3-deazaneplanocin A, suggesting a role for DNA methylation
and histone modifications in the control of the global alterations
in gene expression required for activation.74 75 Our laboratory
described an epigenetic relay pathway requiring activation in
order to drive HSC transdifferentiation. Mice lacking the DNA
methylation reader MeCP2 are attenuated in their liver fibrosis
and mecp2-deficient HSC show reduced levels of fibrogenic
markers collagen 1, TIMP-1 and aSMA.74 PPARγ expression
must be silenced for HSC to activate and acquire their myofibro-
blast phenotype and this is achieved by two concurrent epigen-
etic mechanisms. First, methyl-CpGs within the promoter of
PPARγ recruit MeCP2, which then directs repressive
H3K9me3-modifying enzymes to suppress initiation of tran-
scription. Second, transcriptional elongation is suppressed by
EZH2-mediated H3K27me3 modifications in the downstream
coding region of PPARγ, with de novo expression of EZH2
being dependent on MeCP2.74 However, MECP2 can also
stimulate transcription of multiple profibrogenic genes through
its control of ASH1, an H3K4/H3K36 histone methyltransferase
that activates transcription.76 Hence, MeCP2 is a master epigen-
etic orchestrator of HSC activation.
Increased DNA methylation during HSC activation occurs at
the phosphatase and tensin homolog tumour suppressor ad
Patched 1, correlating with its reduced expression in HSCs.77
This suggested that DNA methylation is subject to turnover
during HSC activation. This concept was confirmed and
extended in a recent study in which the expression of DNMT
and TET enzymes were analysed in both animal models and
human liver disease. Experimental fibrosis was associated with
decreased expression of TET2 and TET3 and was accompanied
by loss of 5-hmC.78 In contrast, DNMTs were generally induced
at the protein level in fibrotic livers, although this was not
accompanied by a change in the global amount of 5-mC.78
Furthermore, in mechanistically distinct human fibrotic liver
disease, common changes were seen and correlated with global
epigenetic changes in experimental liver fibrosis. Both culture-
activated and ex vivo purified activated HSCs displayed
decreased levels of 5-hmC and increased expression of the de
novo DNA methyltransferases DNMT3a/b, consistent with
changes seen in fibrotic human and rodent liver.78 An important
step in this study was genome mapping of sequence-specific
alterations in 5-mC and 5-hmC densities during HSC activation
by reduced representation bisulfite sequencing. Quiescent and
activated HSC displayed distinct 5-mC landscapes across chro-
mosomes 13 to 19, 20, 21 and also of note at the Y chromo-
some.78 The 5-hmC landscape for activated HSC was of lower
density across the genome, although chromosome 9 had a par-
ticularly high density of 5-hmC modifications that were unique
to activated HSC.78 Thus, HSC activation is underpinned by
genome-wide alterations in DNA methylation that are most
likely driven by increased expression of DNMTs and concomi-
tant reduced expression of demethylases.78 The next challenge
will be to determine if methylome remodelling is a direct regula-
tor of HSC phenotype or is merely a consequence of HSC
activation.
As alluded to earlier, histone modifications are induced in
HSC transdifferentiation and liver toxins can influence the activ-
ities of chromatin remodellers. Hepatocytes cultured with free
fatty acids overexpress the ATP-dependent chromatin remodel-
ling proteins Brg1 and Brm, stabilising NF-κB, and this is
required for the development of steatosis, inflammation and
fibrosis in methionine-choline deficient diet fed mice.79 We
recently showed transdifferentiating HSCs cultured directly with
ethanol show altered expression of multiple epigenetic regula-
tors and display an altered chromatin structure.80 MLL1, a
H3K4 methyltransferase associated with activation of transcrip-
tion, was induced by ethanol and recruited to the elastin gene
promoter which was associated with enrichment of the
H3K4me3 mark at this gene and enhanced expression of
elastin.80 A prior study showed that acetylation of H3K9, a tran-
scriptionally active modification is induced in a time-dependent
and dose-dependent manner in HSCs cultured with ethanol.81
These observations highlight the plasticity of the HSC epigen-
ome, its potential to be modulated by environmental factors and
if studied further can provide new mechanistic insights into how
the course of fibrogenesis may be influenced by xenobiotics and
diet.
The progression of chronic human liver disease represents an
increase in fibrotic scar deposition and the out-pacing of liver
healing by regeneration. Currently, very little is known about
the epigenetic control of liver regeneration. However, a recent
study showed that loss of Arid1a, a component of the chromatin
remodelling complexes SWI/SNF, resulted in improved liver
regeneration after partial hepatectomy in mice.82 Conditional
overexpression of Arid1a reduced proliferation in wild type
(WT) animals after chemical injury. The molecular mechanisms
underlying Arid1a-mediated impaired regeneration involve chro-
matin remodelling, ultimately altering transcriptional access by
C/EBPα and E2F4, transcription factors that support terminal
differentiation and antagonise proliferation.
Many studies have documented the differential expression of
numerous miRNAs in HSCs; the biological function of these
miRNAs has been less well studied. However, a recent study
employed genome-wide technology to identify the miR-29
family as a fibrogenic regulator in carbontetrachloride-injured
and bile duct ligated-injured mice.83 The expression of the
miR-29 family was downregulated in these models of experi-
mental fibrosis, and in human liver tissue and serum from
patients with advanced liver disease. Overexpression of miR-29
in HSC reduced collagen expression, moreover TGF-β repressed
miR-29 expression.83 However, in vivo studies confirming a
regulatory function for miR-29 in liver disease are still lacking.
connective tissue growth factor (CTGF) is a well-known soluble
stimulator of fibrogenesis and is upregulated during HSC activa-
tion, along with a reciprocal downregulation of miR-214 which
directly binds the CTGF 30-untranslated region (UTR).84 Of
note, it was also demonstrated that miR-214 is transported by
exosomes and can be delivered to HSCs resulting in the sup-
pression of CTGF 30-UTR activity, reduced expression of CTGF
and inhibition of profibrogenic genes that lie downstream of
CTGF.84 Circulating miR-214 was reported to be decreased in
mice with experimental liver fibrosis, but its presence in circulat-
ing exosomes in this model was not assessed.84 While numerous
miRNAs have been described as regulators of HSC phenotype
and fibrosis progression, studies investigating the functions of
lncRNAs are awaited.
EPIGENETICS AND THE PROGRESSION OF
NON-ALCOHOLIC STEATOHEPATITIS
Non-alcoholic steatohepatitis (NASH) represents the more
severe disease entity of NAFLD, the most common liver disease
in the Western world due to its association with obesity and
type II diabetes. NASH is typically characterised by steatosis,
ballooning hepatocytes and lobular inflammation, with or
without fibrosis. As with other causes of liver disease, only a
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minority of patients with NASH progress to advanced fibrosis,
cirrhosis and/or HCC. Progression of NASH is governed by
host genetics, and the interaction of environmental factors.4
Recent studies have shown that the presence of fibrosis on
biopsy is the key histological determinant of long-term progno-
sis.85 86 Particular excitement surrounds emerging translational
studies that indicate an involvement of DNA methylation in pro-
gression to fibrosis. We have shown, in a small cohort of
well-characterised NASH, that DNA methylation status of key
fibrosis modifier genes loci in liver tissue can stratify patients
according to fibrosis severity.87 Furthermore, a landmark study
examined differential DNA methylation in 69 247 CpG sites in
liver biopsies from mild (F0–2) versus patients with advanced
(F3–4) fibrosis.88 The majority of differentially methylated sites
became hypomethylated with disease progression (76%),
whereas 24% underwent hypermethylation. Methylation corre-
lated with 7% gene transcript levels such as FGFR2, a function-
ing receptor for keratinocyte growth factor, a protein made in
chronic liver disease by stellate cells.88 A similar study was
carried out in liver biopsies from lean controls, obese and
patients with NASH. However, an important aspect of this
study was the use of paired liver biopsies prebariatric and post-
bariatric surgery. This study showed that NAFLD-associated
methylation changes to be partially reversible, and >400-fold
enrichment in NRF1, HSF1 and ESRRA transcription factor
binding sites.89 An important caveat to these studies is the ana-
lysis of DNA methylation in whole liver biopsies; the observed
differences in DNA methylation density may simply reflect cel-
lular or architectural changes inherent in the fibrogenic process.
We have demonstrated that when areas enriched for myofibro-
blasts are separated from hepatocytes by laser capture microdis-
section, DNA methylation status at specific gene loci are distinct
and specific,90 hence the analysis of DNA methylation in whole
tissue has limited power for revealing mechanistic insights.
A further caveat is that causality cannot be attributed to DNA
methylation; longitudinal studies are needed to clarify if differ-
ences in DNA methylation at specific loci are predictive of
progression to fibrosis. Concrete evidence of causality will
require complex experimental investigations where specific
methyl-CpG sites are manipulated in the context of a model of
NASH-induced fibrogenesis .However, despite these caveats we
can anticipate that the identification of sites of differential DNA
methylation associated with fibrosis will lead to the develop-
ment of new diagnostic biomarkers. Indeed, our laboratory have
recently reported that fibrosis is associated with changes in
DNA methylation density at the PPARγ promoter in circulating
cell-free DNA isolated from patient plasma.90 Moreover, quanti-
fication of this epigenetic mark by pyrosequencing provided a
powerful stratification tool, being able to clearly identify
patients with NASH that had progressed to severe fibrosis.90
Further validation trials are ongoing with the aim of establishing
the concept of quantification of DNA methylation from cell-free
DNA as a liquid biomarker.
An emerging concept is the interplay between genetic and epi-
genetic variants in determining gene expression and NAFLD
disease progression. As an example, an interesting study
attempted to analyse both aberrant DNA methylation and its
role in known genetic single nucleotide polymorphisms (SNPs)
associated with severe NAFLD. The rs738409 Il148Met SNP in
PNPLA3 is a well-known genetic modifier of NAFLD,91
although its regulation and function is currently unclear. This
study found a differentially methylated region in the PNPLA3
promoter that was significantly hypermethylated in the livers of
more severe (F3–4) fibrotic NASH, and was inversely correlated
with mRNA levels in the same liver biopsy specimens, signifi-
cantly with the GG genotype.92
A number of experimental studies have demonstrated control
of hepatic lipid and carbohydrate metabolism by histone modi-
fying enzymes. Normal circadian changes in lipid synthesis are
associated with dynamic histone acetylation patterns of target
genes in liver chromatin. This is controlled by histone deacety-
lase 3 (HDAC3) and its depletion promotes development of
hepatic steatosis.93 HDAC3 can also integrate hepatic lipid and
carbohydrate metabolism; mice with liver-specific depletion of
Hdac3 had higher insulin sensitivity compared with WT mice,
despite severe hepatic steatosis.94 This suggests a role for Hdac3
in reprogramming metabolites from usage in hepatic glucose
production, to lipid synthesis and storage.94 Finally, the tran-
scriptional activity of carbohydrate-responsive element-binding
protein (ChREBP), a key transcriptional regulator of both lipo-
genic and glycolytic gene expression, is controlled by p300
which acetylates ChREBP on Lys672, enhancing its recruitment
to its target gene promoters.95 Liver-specific p300 overexpres-
sion resulted in hepatic steatosis, confirmed in animal models of
T2DM and obesity.95
The functions of ncRNAs in NASH have so far extended only
to miRNAs, of which, many have been reported to be differen-
tially expressed. miR-122 is well described regulator of lipid and
cholesterol metabolism, accounting for 70% of the total liver
miRNA pool, and is downregulated in NASH livers.96 More
recently, there has been interest in whether miRNAs can serve
as novel biomarkers of NAFLD. Elevated serum levels of
miR-122, miR-34a and miR-16 were found in patients with
NAFLD as compared with controls.97 miR-122 and miR-34a
were both positively correlated with disease severity from stea-
tosis to steatohepatitis.97 miR-122 was also correlated with liver
enzymes, serum lipids and histological assessment.98 A recent
study analysed a greater number of circulating miRNAs using a
PCR-based array.98 Among 84 miRNAs analysed, circulating
miR-122 was upregulated in NASH versus simple steatosis
(3.1-fold) and controls (7.2-fold). Liver miR-122 was downre-
gulated in NASH as prior studies demonstrated. Additionally,
miR-192 and miR-375 were elevated in NASH serum
compared with steatosis, and downregulated in NASH liver.
A circulating miRNA signature of NAFLD appears attractive,
but the predictive power of such a signature was only fair
(AUROC ∼0.7).98
CAN LIVER DISEASE BE INHERITED?
Major advances in the field of transgenerational epigenetic
inheritance have reopened a debate on the validity of Lamarck’s
original theory that species may adapt phenotype in response to
environmental influences. It is only recently that studies in
mammals have provided evidence that exposure to environmen-
tal stressors can drive stably inherited phenotypic adaptations in
offspring that are inherited by epigenetic, rather than genetic
mechanisms. Intriguingly, some of these studies concern the
development of liver disease. For example, male inbred mice fed
a low protein diet had offspring that increased liver expression
of genes involved in lipid and cholesterol metabolism.99
Ancestral history of liver fibrosis in male outbred rats elicits a
remodelling of DNA methylation in key fibrosis genes promo-
ters, suppressing liver fibrosis in offspring.100 Importantly, com-
parable remodelling was demonstrated at similar loci in human
fibrotic NAFLD liver tissue.100 Human studies in this field are
lacking. However, a recent study in lean versus obese males
found that spermatozoa had distinct sncRNA and DNA methy-
lation signatures, particularly at loci controlling brain
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development and function, and that the epigenome could be
remodelled after bariatric surgery, suggesting a mechanism for
inheritance of metabolic dysfunction in progeny.101 There is
also recent evidence for a heritable component to human
NAFLD, ranging from 20% to 100%;102 103 the contribution of
epigenetic inheritance has recently been examined. A study con-
ducted in monozygotic and dizygotic twins examined the rele-
vance of miRNAs in discordant NAFLD phenotypes. In this
study, 40 twin pairs underwent liver proton density fat fraction
MRI to estimate liver fat content and serum miR profiling. Six
twin pairs were discordant for NAFLD and a panel of 10
miRNAs discriminated between discordant pairs. Of these,
miR331-3p and miR-30c were both highly heritable and targets
included lipid and energy metabolism pathways.104 Future inves-
tigations aimed at clarifying the role of epigenetic imprinting in
human liver disease are eagerly anticipated.
EMERGING EPIGENETIC THERAPIES
The discovery of novel, modifiable epigenetic targets has paved
the way for the emergence of molecular-based epigenetic
therapy; a table of registered trials of epigenetic drugs in liver
disease is shown in table 1. The dynamism of the epigenome is
relevant to drug development, as specific epigenetic alterations
may be modified with treatment.
miRNAs
Perhaps the best example of recent translational epigenetic
therapy in liver disease is the miR-122 antagonist miravirsen, a
locked nucleic acid-modified DNA phosphorothioate antisense
oligonucleotide that sequesters mature miR-122 in a stable het-
eroduplex, inhibiting its function. Preclinical studies showed
that miR-122 is essential for stability and propagation of HCV
RNA.105 The 50-UTR of HCV is highly conserved across all
HCV genotypes106 and contains two closely spaced target sites,
enhancing viral protein expression and protecting HCV RNA
from nucleolytic degradation.105 In vivo studies in chimpanzees
showed a marked suppression of plasma and liver HCV
RNA,107 without evidence of resistant mutations at the two
miR-122 binding sites in animal that received the highest dose
of miravirsen. No adverse events were seen in phase I trials in
healthy volunteers,108 leading to a phase IIa study in 36, treat-
ment naïve, patients with non-cirrhotic chronically infected
with HCV genotype 1. Dose-dependent reductions in HCV
RNA levels were observed after 5 weekly administrations of
miraversen, with no dose limiting adverse events.24 Notable
benefits of miravirsen include a host factor antagonist with a
high barrier to resistance, and likely cross genotype effect.
Conclusions should however be tempered; germline deletion of
miR-122 in mice resulted in steatohepatitis, and hepatocarcino-
genesis.109 Also as observed in the phase IIa study, miR-122
antagonism lowered serum cholesterol levels demonstrating
other miR-122 targets are affected during therapy.24 Although
targeting miRNAs has shown promise in HCC,110 until more is
known regarding the biology of miRNAs, a robust long-term
therapeutic is not currently feasible for human HCC and liver
fibrosis, and research is ongoing.
HDAC inhibitors
The acetylation of histones is carried out by opposing enzymes,
histone acetyl transferases and HDAC. HDACs catalyse the
removal of acetyl groups from histone, compacting chromatin
and silencing gene expression. Dysregulated expression of
HDACs has been implicated in several cancers, including HCC.
Overexpression of HDACs have been shown in 30%–50% of
HBV-related HCCs,111 and overexpression of HDAC1 corre-
lated with a high incidence of portal vein invasion, poor histo-
logical differentiation, more advanced TNM (tumour node
metastases) stage and was an independent prognostic of HCC in
patients after hepatic resection.112 Overexpression of HDAC3 is
also correlated with advanced tumour stage and early recurrence
after surgery.113 HDAC inhibitors (HDACi) have had favourable
preclinical results, and induce apoptosis in tumour cells114
Pabinostat, a hydroxamic acid, pan-HDACi, when combined
with sorafenib, demonstrated efficacy in HCC xenograft
models.115 In humans, efficacy of HDACi has been demon-
strated in advanced cutaneous and peripheral T-cell lymph-
oma.116 A recent phase I/II clinical trial of resminostat in 57
patients with HCC and radiological progression on sorafenib
treatment was recently reported; median time to progression
and overall survival were 6.5 and 8.0 months for combination
therapy.117 The results from resminostat monotherapy were
dismal, but suggest that it may restore sensitivity to sorafenib,
and be a potential therapeutic option.117 No safety issues were
reported in this study, although the most common adverse
events were GI upset, thrombocytopenia and fatigue. Another
prior phase I/II clinical trial of belinostat monotherapy for
advanced HCC reported disappointing progression-free survival
2.6 months and overall survival of 6.6 months.118 In vitro and
in vivo studies suggest that HDAC are also upregulated in
chronic fibrotic liver disease.119 HDACi block myofibroblast
transdifferentiation and fibrogenesis in animal models.119 120
Currently, no clinical trials have evaluated the efficacy of
HDACi in human chronic liver disease; deeper understanding of
HDAC substrate, activities and the molecular mechanisms
underpinning HDACi inhibition is necessary for development of
inhibitors with greater specificity. Notably, histones are the sub-
strate for HDACs and act as acetyl-lysine erasers on non-histone
proteins such as p53, NF-κB subunits and cytoskeleton pro-
teins.121 There are several 2nd generation HDACi in develop-
ment, targeting individual HDACs rather than promiscuously; it
is hoped that they may shed light on the mechanisms underlying
individual HDACs, and also mitigate the toxicity associated with
current HDACi.122
HDAC activators
SIRT1 is a class III HDAC; its action is nicotinamide adenine
dinucleotide (NAD+)-dependent, and is regulator of metabol-
ism and ageing,123 hallmarks of NAFLD. As mice age, liver
expression of SIRT1 is reduced.124 When mice with liver-
specific knockout of SIRT1 are challenged with a high fat diet,
hepatic steatosis, inflammation and endoplasmic reticulum
Table 1 Emerging epigenetic therapies in HCC. Clinicaltrials.gov
accessed on 15th July 2016
Agent Phase Target Primary outcome
Clinical trials
identifier
SGI-110 II DNMT DCR at 16 weeks NCT01752933
CUDC-101 Ib HDAC/EGFR/Her2 AE NCT01171924
Vorinostat I HDAC MTD NCT01075113
MRX34 I miR-RX34 MTD NCT01829971
PXD-101 I/II HDAC MTD/TR NCT00321594
Resminostat II HDAC PFSR at 12 weeks NCT00943449
AE, adverse events; DCR, Disease Control Rate; DNMT, DNA methyltransferase; EGFR,
epidermal growth factor receptor; HDAC, histone deacetylase; HER2, human
epidermal growth factor receptor 2; MTD, maximum tolerated dose;
PRSF, progression-free survival rate; TR, tumour response.
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stress results due to altered PPARα signalling.125 Equally, mice
treated with SIRT1 activators such as resveratrol were pre-
vented from developing diet-induced NAFLD.126 127 In obese
humans, liver expression of SIRT1 increased after extensive
weight loss.128 However, patients with NAFLD treated with 8
weeks of resveratrol did not improve hepatic steatosis (as mea-
sured by MRI) or insulin resistance, when compared with
placebo.129 Indeed, markers of hepatic inflammation such as
alanine aminotransferases increased.129 Thus, further studies
are needed to clarify a role for SIRT1 activators in patients
with NAFLD.
DNMT inhibitors
Targeting aberrant DNA methylation in HCC using DNMT
inhibitors is currently being tested in phase II trials.
Guadecitabine (SGI-110) is a stabilising dinucleotide comprising
deoxyguanosine and the DNA demethylation agent decitabine
(2-deoxy-50-aza-cytidine), currently an Food and Drug
Administration-approved therapy for myelodysplastic syndrome.
Experimental data suggest that combination therapy with
SGI-110 may sensitise HCC cells to oxaloplatin.130 In xenograft
studies performed in athymic nude mice, combination therapy
reduced tumour growth and decrease on Ki67 levels, suggesting
reduced cell proliferation.130 Results from a now complete
phase II clinical trial are now awaited. Many experimental
studies have identified DNA methylation as a potential target in
the treatment of chronic fibrotic liver disease. However, there
are currently no clinical trials testing DNMTi in liver fibrosis.
CONCLUSIONS
This review aims to highlight key areas in which epigenetic
mechanisms influence liver disease phenotype by effecting the
underlying cellular biology, and potential clinical utility, as sum-
marised in figure 2. Advances in non-invasive risk stratification
are beginning to be realised, and new epigenetic drugs are being
developed and tested in clinical trials. The current challenge for
hepatologists in providing effective healthcare for their patients
is the need for better diagnostics, prognostics and therapeutics,
personalised to those who would most benefit. While genetic
factors are undoubtedly important in this endeavour, the oppor-
tunity provided by better understanding and exploitation of the
fine-tuning, epigenetic mechanisms operating in liver disease,
promises to drive forward an unprecedented advance in preci-
sion medicine.
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